A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Recruiting

Phase 2

Encorafenib & BinimetinibA Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Sponsor:

SWOG Cancer Research Network

Code:

NCT04511013

Conditions

Acral Lentiginous Melanoma

Clinical Stage IV Cutaneous Melanoma AJCC v8

Metastatic Cutaneous Melanoma

Metastatic Malignant Neoplasm in the Brain

Metastatic Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Binimetinib

Encorafenib

Ipilimumab

Nivolumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-19. This information was provided to ClinicalTrials.gov by SWOG Cancer Research Network on 2024-08-16.